Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Rosmantuzumab||Phase I||Actionable||In a Phase I clinical trial, treatment with OMP-131R10 was well-tolerated and demonstrated preliminary efficacy in patients with advanced solid tumors, with 37% (7/19) of patients achieving stable disease (EORTC-NCI-AACR 2017; Abstract nr 68).||detail...|
|PubMed Id||Reference Title||Details|
|Initial results from a phase 1a/b study of OMP-131R10, a first-in-class anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC)||Full reference...|